Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cell Oncol (Dordr)
Glavni autori: Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Format: Artigo
Jezik:Inglês
Izdano: Springer Netherlands 2015
Teme:
Original Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4555235/
https://ncbi.nlm.nih.gov/pubmed/25665527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-015-0218-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items